bioRxiv / medRxiv
open access
Real-World Effectiveness of Maternal RSVpreF Vaccination and Durability of Infant Protection
In this test-negative study, the effectiveness of the maternal RSVpreF vaccine among infants <6 months was 73.9% against medically attended respiratory syncytial virus (RSV) infection and 86.3% against RSV-associated hospitalization. Maternal RSVpreF and nirsevimab had comparable initial effectivene
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in Newborns.#301702
- An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study#1244048
- Maternal RSVpreF Vaccine Effectiveness Against Respiratory Syncytial Virus in Hospitalized Infants.#469438
- Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.#125944
- Evaluation of RSV/Flu-01E Vaccine for the Prevention of RSV Infection in Volunteers Aged 18 to 59 Years and Over 60 Years#880567
Record · ID 1349084
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive